Tela Bio Inc Reports Results For The Quarter Ended June 30: Earnings Summary
TELA Bio Inc reports results for the quarter ended June 30 - Earnings Summary
TELA Bio Inc TELA.OQ reported a quarterly adjusted loss of 20 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -22 cents. The mean expectation of five analysts for the quarter was for a loss of 18 cents per share. Wall Street expected results to range from -20 cents to -15 cents per share.
Revenue fell 4.5% to $19.29 million from a year ago; analysts expected $20.01 million.
TELA Bio Inc's reported EPS for the quarter was a loss of 20 cents.
The company reported a quarterly loss of $11.26 million.
TELA Bio Inc shares had risen by 16.0% this quarter and lost 26.3% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 1.2% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"
Wall Street's median 12-month price target for TELA Bio Inc is $2.00, about 56.5% above its last closing price of $0.87
This summary was machine generated from LSEG data August 10 at 09:42 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.18 | -0.20 | Missed |
Mar. 31 2026 | -0.19 | -0.21 | Missed |
Dec. 31 2025 | -0.18 | -0.17 | Beat |
Sep. 30 2025 | -0.20 | -0.19 | Beat |
Recent news on TELA Bio
See all newsBrief: Tela Bio - Receives FDA 510(K) Clearance For Liora Monofilament Scaffold For Soft Tissue Reinforcement
Tela Bio Inc Reports Results For The Quarter Ended June 30: Earnings Summary
TELA Bio Q2 revenue falls on lower OviTex PRS volumes, withdraws outlook
Brief: TELA Bio Q2 Revenue USD 19.291 Million Vs. IBES Estimate USD 20 Million
Tela Bio Inc Expected To Post A Loss Of 18 Cents A Share: Earnings Preview